OMER catalyst calendar

OMEROS CORP

Upcoming catalysts
2
Cash runway
27.3 months
Cash & investments
$132M
Phase 3 programs
2

OMEROS CORP is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 3, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 27.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 21 concluded trials, 76% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Trial Milestone Phase 2

Track OMER alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open OMER in the tracker

Recent history

DateEventTypePhase
August 13, 2026 8-K filed: Leadership change Corporate —
August 12, 2026 Quarterly results filed (8-K) Earnings —
July 20, 2026 8-K filed: Other event Filing —
July 6, 2026 8-K filed: Other event Filing —
June 18, 2026 8-K filed: Other event Filing —
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 Quarterly results filed (8-K) Earnings —
January 15, 2026 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN Trial Milestone Phase 2
January 7, 2026 Quarterly results filed (8-K) Earnings —
December 29, 2025 8-K filed: Other event Filing —
December 15, 2025 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Trial Milestone Phase 2
December 1, 2025 8-K filed: Acquisition completed, Other event Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
November 3, 2025 Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria Trial Milestone Phase 1
October 15, 2025 8-K filed: Material agreement, Other event Corporate —
August 14, 2025 Quarterly results filed (8-K) Earnings —
July 25, 2025 8-K filed: Other event Filing —
May 15, 2025 Quarterly results filed (8-K) Earnings —
May 6, 2025 8-K filed: Other event Filing —
October 10, 2024 Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab Trial Milestone Phase 2
January 12, 2024 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy Trial Milestone Phase 3
February 2, 2021 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Trial Milestone Phase 3
August 25, 2020 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Trial Milestone Phase 2
January 30, 2020 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.